{"entity":"abbvie","id":"ent_abbvie","name":"AbbVie","wikidata":"Q14662364","page":"https://asof.is/record/abbvie","summary":"AbbVie is a pharmaceutical company, headquartered in North Chicago. It reported revenue of $61.16B for the period ended December 31, 2025.","title":"AbbVie: revenue $61.16B","key_facts":[{"label":"Headquarters","value":"North Chicago","claim":"clm_E74DBC8CCF1E"},{"label":"Revenue","value":"$61.16B","recorded":"61,160,000,000 United States dollar","note":"to 2025-12-31","claim":"clm_4A7BE8ED0078"},{"label":"Ticker","value":"ABBV · NYSE","claim":"clm_B87EDEAECF6B"}],"faq":[{"question":"Where is AbbVie headquartered?","answer":"North Chicago."},{"question":"What is AbbVie's revenue?","answer":"$61.16B for the period ended December 31, 2025."}],"as_of":"2026-11-08","known_by":null,"since":null,"fact_pages":[{"predicate":"headquarters","page":"https://asof.is/record/abbvie/headquarters","md":"https://asof.is/record/abbvie/headquarters.md","json":"https://asof.is/v1/entities/abbvie/headquarters"},{"predicate":"revenue","page":"https://asof.is/record/abbvie/revenue","md":"https://asof.is/record/abbvie/revenue.md","json":"https://asof.is/v1/entities/abbvie/revenue"},{"predicate":"net_income","page":"https://asof.is/record/abbvie/net_income","md":"https://asof.is/record/abbvie/net_income.md","json":"https://asof.is/v1/entities/abbvie/net_income"},{"predicate":"operating_income","page":"https://asof.is/record/abbvie/operating_income","md":"https://asof.is/record/abbvie/operating_income.md","json":"https://asof.is/v1/entities/abbvie/operating_income"},{"predicate":"quarterly_revenue","page":"https://asof.is/record/abbvie/quarterly_revenue","md":"https://asof.is/record/abbvie/quarterly_revenue.md","json":"https://asof.is/v1/entities/abbvie/quarterly_revenue"}],"products":[],"coverage":{"entity":"abbvie","name":"AbbVie","kind":"organization","sources":[{"source":"wikidata","item":"Q14662364","covers":"dated statements whose reference URL is the source: leadership, ownership, names, founding, headquarters; never financial figures"},{"source":"wikidata-products","covers":"products it makes, develops or publishes, as released claims, when the release date cites a reference URL; a rotating scan, a few dozen entities a run"},{"source":"sec","cik":1551152,"ticker":"ABBV","covers":"annual and quarterly figures from XBRL, registrant name, tickers and fiscal year end; officer and director changes (8-K Item 5.02) and material events (other 8-K items)"}],"holds":{"claims":402,"open":18,"retracted":0,"first":"2010-12-31","predicates":{"total_equity":{"claims":56,"open":1,"kind":"fact"},"quarterly_net_income":{"claims":34,"open":1,"kind":"fact"},"total_assets":{"claims":56,"open":1,"kind":"fact"},"quarterly_revenue":{"claims":45,"open":1,"kind":"fact"},"cash_and_equivalents":{"claims":61,"open":1,"kind":"fact"},"shares_outstanding":{"claims":55,"open":1,"kind":"fact"},"quarterly_operating_income":{"claims":45,"open":1,"kind":"fact"},"net_income":{"claims":12,"open":1,"kind":"fact"},"revenue":{"claims":15,"open":1,"kind":"fact"},"operating_income":{"claims":15,"open":1,"kind":"fact"},"state_of_incorporation":{"claims":1,"open":1,"kind":"identifier"},"sic_industry":{"claims":1,"open":1,"kind":"identifier"},"registrant_name":{"claims":1,"open":1,"kind":"fact"},"ticker":{"claims":1,"open":1,"kind":"identifier"},"listed_on":{"claims":1,"open":1,"kind":"fact"},"cik":{"claims":1,"open":1,"kind":"identifier"},"fiscal_year_end":{"claims":1,"open":1,"kind":"identifier"},"headquarters":{"claims":1,"open":1,"kind":"fact"}}},"freshness":[{"origin":"sec","label":"SEC EDGAR filings: XBRL figures, registry fields, 8-K officer changes and events (sec_ingest.py, sec_officers.py, sec_events.py)","claims":402,"last_added":"2026-11-08","last_checked":"2026-11-08","last_verified":null}],"gaps":["ceo: none public; unknown, not absent: a claim is published only once checked against its source","posts: no official feed speaks for it (pipeline/feeds.json primary_for); what it holds comes from Wikidata, filings and other publishers' feeds"],"group":[],"group_complete":true,"rule":"sources: what the pipeline reads for this entity, from its config (pipeline/entities.json, feeds.json, sec_companies.json, huggingface_authors.json). holds: its public claims by predicate; open is held today; kind fact is what entity_state answers by default, event is for timeline. freshness, per ingest (origin): last_added is the day it last put a new claim here (first_seen_at), last_checked the day one was last checked against its source (checked_on), last_verified the day reverify.py last confirmed one against Wikidata (value_json.verified_at). Only checked claims are public, so a fact missing here is unknown, not absent. gaps: what the record does not cover for this entity, so an empty answer is not read as news."},"claims":[{"id":"clm_A17F69D94691","predicate":"cash_and_equivalents","value":"10,774,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cash and equivalents: 10,774,000,000 United States dollar\", as of 2026-09-30. Claim clm_A17F69D94691, https://asof.is/claim/clm_A17F69D94691, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_A17F69D94691","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:CashAndCashEquivalentsAtCarryingValue in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_CD48BB22552C","predicate":"cik","value":"0001551152","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie cik: 0001551152\", undated. Claim clm_CD48BB22552C, https://asof.is/claim/clm_CD48BB22552C, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_CD48BB22552C","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_D5837D9B7367","predicate":"fiscal_year_end","value":"12-31","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie fiscal year end: 12-31\", undated. Claim clm_D5837D9B7367, https://asof.is/claim/clm_D5837D9B7367, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_D5837D9B7367","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_E74DBC8CCF1E","predicate":"headquarters","value":"North Chicago","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie headquarters: North Chicago\", undated. Claim clm_E74DBC8CCF1E, https://asof.is/claim/clm_E74DBC8CCF1E, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_E74DBC8CCF1E","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_BBC331549951","predicate":"listed_on","value":"NYSE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie listed on: NYSE\", undated. Claim clm_BBC331549951, https://asof.is/claim/clm_BBC331549951, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_BBC331549951","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_2A3E6A20A337","predicate":"net_income","value":"4,226,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie net income: 4,226,000,000 United States dollar\", as of 2025-12-31. Claim clm_2A3E6A20A337, https://asof.is/claim/clm_2A3E6A20A337, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm.","url":"https://asof.is/claim/clm_2A3E6A20A337","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-20T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-K FY2025, filed 2026-02-20"}},{"id":"clm_D4AF640165D7","predicate":"operating_income","value":"15,075,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie operating income: 15,075,000,000 United States dollar\", as of 2025-12-31. Claim clm_D4AF640165D7, https://asof.is/claim/clm_D4AF640165D7, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm.","url":"https://asof.is/claim/clm_D4AF640165D7","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-20T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-K FY2025, filed 2026-02-20"}},{"id":"clm_B8246C4E0E64","predicate":"quarterly_net_income","value":"4,218,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly net income: 4,218,000,000 United States dollar\", as of 2026-09-30. Claim clm_B8246C4E0E64, https://asof.is/claim/clm_B8246C4E0E64, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_B8246C4E0E64","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:NetIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_5AF8A08D6F94","predicate":"quarterly_operating_income","value":"6,267,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly operating income: 6,267,000,000 United States dollar\", as of 2026-09-30. Claim clm_5AF8A08D6F94, https://asof.is/claim/clm_5AF8A08D6F94, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_5AF8A08D6F94","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:OperatingIncomeLoss in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_DA52AAE1BFB4","predicate":"quarterly_revenue","value":"17,404,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie quarterly revenue: 17,404,000,000 United States dollar\", as of 2026-09-30. Claim clm_DA52AAE1BFB4, https://asof.is/claim/clm_DA52AAE1BFB4, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_DA52AAE1BFB4","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_78F47A4D8706","predicate":"registrant_name","value":"AbbVie Inc.","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie registrant name: AbbVie Inc.\", undated. Claim clm_78F47A4D8706, https://asof.is/claim/clm_78F47A4D8706, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_78F47A4D8706","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_4A7BE8ED0078","predicate":"revenue","value":"61,160,000,000 United States dollar","valid_from":"2025-12-31","valid_to":null,"published":"2026-02-20","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie revenue: 61,160,000,000 United States dollar\", as of 2025-12-31. Claim clm_4A7BE8ED0078, https://asof.is/claim/clm_4A7BE8ED0078, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm.","url":"https://asof.is/claim/clm_4A7BE8ED0078","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000008/0001551152-26-000008-index.htm","tier":"primary","publisher":"SEC EDGAR 10-K FY2025","published_at":"2026-02-20T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Revenues in 10-K FY2025, filed 2026-02-20"}},{"id":"clm_54135339A00E","predicate":"shares_outstanding","value":"1,767,616,306 shares","valid_from":"2026-10-26","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie shares outstanding: 1,767,616,306 shares\", as of 2026-10-26. Claim clm_54135339A00E, https://asof.is/claim/clm_54135339A00E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_54135339A00E","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"dei:EntityCommonStockSharesOutstanding in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_60D3FAD20B06","predicate":"sic_industry","value":"Pharmaceutical Preparations (2834)","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie sic industry: Pharmaceutical Preparations (2834)\", undated. Claim clm_60D3FAD20B06, https://asof.is/claim/clm_60D3FAD20B06, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_60D3FAD20B06","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_50468CC9D02A","predicate":"state_of_incorporation","value":"DE","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie state of incorporation: DE\", undated. Claim clm_50468CC9D02A, https://asof.is/claim/clm_50468CC9D02A, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_50468CC9D02A","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_B87EDEAECF6B","predicate":"ticker","value":"ABBV","valid_from":null,"undated":true,"valid_to":null,"published":null,"recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie ticker: ABBV\", undated. Claim clm_B87EDEAECF6B, https://asof.is/claim/clm_B87EDEAECF6B, accessed 2026-11-08. Source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152.","url":"https://asof.is/claim/clm_B87EDEAECF6B","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001551152","tier":"primary","publisher":"SEC EDGAR","published_at":null}],"evidence":{"by":"sec-filing","on":"2026-11-08"}},{"id":"clm_0DE2793ECF77","predicate":"total_assets","value":"147,680,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total assets: 147,680,000,000 United States dollar\", as of 2026-09-30. Claim clm_0DE2793ECF77, https://asof.is/claim/clm_0DE2793ECF77, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_0DE2793ECF77","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:Assets in 10-Q Q3 FY2026, filed 2026-11-03"}},{"id":"clm_FA883B408C6E","predicate":"total_equity","value":"-4,583,000,000 United States dollar","valid_from":"2026-09-30","valid_to":null,"published":"2026-11-03","recorded":"2026-11-08","citation":{"plain":"AsOf. \"AbbVie total equity: -4,583,000,000 United States dollar\", as of 2026-09-30. Claim clm_FA883B408C6E, https://asof.is/claim/clm_FA883B408C6E, accessed 2026-11-08. Source: https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm.","url":"https://asof.is/claim/clm_FA883B408C6E","accessed":"2026-11-08"},"confidence":0.95,"status":"valid","assertable":true,"superseded_by":null,"sources":[{"url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115226000037/0001551152-26-000037-index.htm","tier":"primary","publisher":"SEC EDGAR 10-Q Q3 FY2026","published_at":"2026-11-03T00:00:00+00:00"}],"evidence":{"by":"sec-filing","on":"2026-11-08","fact":"us-gaap:StockholdersEquity in 10-Q Q3 FY2026, filed 2026-11-03"}}],"legend":{"dates":"valid_from: when the claim took effect (a period figure: the day its period closed). published: the earliest day a source on the record published it (a filing's filing date, a post's date; null when no source carries one). recorded: the day AsOf first held it. A figure can take effect weeks before it is published.","citation":"citation: how to cite the row (plain: one sentence with the value, its as-of date, the claim id and URL, the day answered and the primary source; url: the claim page; accessed: the day answered). APA and BibTeX forms are on the claim page.","why_not":{},"checked_by":{"sec-filing":"parsed from the SEC filing"}}}